GlaxoSmithKline (GSK) Gets a Hold From Barclays
GlaxoSmithKline To Go Ex-Dividend On May 16th, 2025 With 0.42909 USD Dividend Per Share
AlphaValue/Baader Europe Notes GSK's 'Healthy' Start to FY25 After Q1 Beat
FDA to Tighten Vaccine Approval Requirements: Reports
Trump Administration Said to Be Investing $500M on Developing Universal Vaccines
Goldman Sachs Sticks to Its Hold Rating for GlaxoSmithKline (GSK)
Research Alert: CFRA Keeps Hold Opinion On Adss Of Gsk
GSK Plc (GSK) Q1 2025 Earnings Conference Call Transcript Summary
European Equities Traded in the US as American Depositary Receipts Drop Sharply in Wednesday Trading
GlaxoSmithKline (GSK) Gets a Hold From UBS
Sector Update: Health Care Stocks Decline Pre-Bell Wednesday
Sector Update: Health Care
US Economy Shrinks in Q1, Driving Premarket Losses for US Equity Futures
6-K: Report of foreign private issuer (related to financial reporting)
Express News | GSK Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Raised Its FY25 Adjusted EPS Guidance. Also, the Company Raised Its FY25 Sales Guidance Above Estimates
Jefferies Remains a Hold on GlaxoSmithKline (GSK)
GSK Posts Q1 Beat Thanks to Specialty Medicines
GSK Q1 Core Earnings, Revenue Increase
GSK Investors Turn to U.S. Policy Outlook After Solid Results -- Market Talk
GSK Affirms Its FY25 Guidance And Expects Its Turnover To Increase Between 3%-5% And Core Operating Profit To Increase Between 6%-8%. Core EPS Is Expected To Increase Between 6%-8%